Functional variants at the 21q22.3 locus involved in breast cancer progression identified by screening of genome-wide estrogen response elements.

Abstract:

INTRODUCTION:Estrogen forms a complex with the estrogen receptor (ER) that binds to estrogen response elements (EREs) in the regulatory region of estrogen-responsive genes and regulates their transcription. Sequence variants in the regulatory regions have the potential to affect the transcription factor-regulatory sequence interaction, resulting in altered expression of target genes. This study explored the association between single-nucleotide polymorphisms (SNPs) within the ERE-associated sequences and breast cancer progression. METHODS:The ERE-associated sequences throughout the whole genome that have been demonstrated to bind ERα in vivo were blasted against online information from SNP data sets and 54 SNPs located adjacent to estrogen-responsive genes were selected for genotyping in two independent cohorts of breast cancer patients: 779 patients in the initial screening stage and another 888 in the validation stage. Deaths due to breast cancer or recurrence of breast cancer were defined as the respective events of interest, and the hazard ratios of individual SNPs were estimated based on the Cox proportional hazards model. Furthermore, functional assays were performed, and information from publicly available genomic data and bioinformatics platforms were used to provide additional evidence for the associations identified in the association analyses. RESULTS:The SNPs at 21q22.3 ERE were significantly associated with overall survival and disease-free survival of patients. Furthermore, these 21q22.3 SNPs (rs2839494 and rs1078272) could affect the binding of this ERE-associated sequence to ERα or Rad21 (an ERα coactivator), respectively, which resulted in a difference in ERα-activated expression of the reporter gene. CONCLUSION:These findings support the idea that functional variants in the ERα-regulating sequence at 21q22.3 are important in determining breast cancer progression.

journal_name

Breast Cancer Res

authors

Hsiung CN,Chu HW,Huang YL,Chou WC,Hu LY,Hsu HM,Wu PE,Hou MF,Yu JC,Shen CY

doi

10.1186/s13058-014-0455-1

subject

Has Abstract

pub_date

2014-10-09 00:00:00

pages

455

issue

5

eissn

1465-5411

issn

1465-542X

pii

s13058-014-0455-1

journal_volume

16

pub_type

杂志文章
  • Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.

    abstract:INTRODUCTION:We present a fully automated method for deriving quantitative measures of background parenchymal enhancement (BPE) from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and perform a preliminary evaluation of these measures to assess the effect of risk-reducing salpingo-oophorectomy (R...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0577-0

    authors: Wu S,Weinstein SP,DeLeo MJ 3rd,Conant EF,Chen J,Domchek SM,Kontos D

    更新日期:2015-05-19 00:00:00

  • CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.

    abstract:INTRODUCTION:Studies on the association between the cytochrome P450c17alpha gene (CYP17) 5'-untranslated region MspA1 genetic polymorphism and breast cancer risk have yielded inconsistent results. Higher levels of estrogen have been reported among young nulliparous women with the A2 allele. Therefore we assessed the im...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1027

    authors: Verla-Tebit E,Wang-Gohrke S,Chang-Claude J

    更新日期:2005-01-01 00:00:00

  • Targeted therapies in breast cancer: are heart and vessels also being targeted?

    abstract::The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of car...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3142

    authors: Criscitiello C,Metzger-Filho O,Saini KS,de Castro G Jr,Diaz M,La Gerche A,de Azambuja E,Piccart-Gebhart MJ

    更新日期:2012-06-19 00:00:00

  • Breast cancer risk perception: what do we know and understand?

    abstract::Women's perceptions of breast cancer risk are largely inaccurate and are often associated with high levels of anxiety about cancer. There are interesting cultural differences that are not well researched. Genetic risk counselling significantly improves accuracy of women's perceptions of risk, but not necessarily to th...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr83

    authors: Hopwood P

    更新日期:2000-01-01 00:00:00

  • Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.

    abstract:BACKGROUND:Chromogenic in situ hybridization (CISH) is emerging as a practical, cost-effective, and valid alternative to fluorescent in situ hybridization in testing for gene alteration, especially in centers primarily working with immunohistochemistry (IHC). METHODS:We assessed Her-2/neu alteration using CISH on form...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr915

    authors: Madrid MA,Lo RW

    更新日期:2004-01-01 00:00:00

  • On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.

    abstract::The increasing importance of signal transducer and activator of transcription 3 (STAT3) expression in human cancers has led several laboratories to examine in detail the expression of one of its major negative regulators in oncogenesis--the T-cell protein tyrosine phosphatase, nonreceptor type 2 (PTPN2). A recent pape...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章,评审

    doi:10.1186/bcr3437

    authors: Tremblay ML

    更新日期:2013-07-31 00:00:00

  • Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

    abstract:INTRODUCTION:Human epidermal growth factor receptor-2 (HER2) gene amplification (HER2+) drives tumor cell growth and survival in ~25% of breast cancers. HER2 signaling activates the type I phosphoinositide 3-kinase (PI3K), upon which these tumors rely. Consequently, inhibitors of HER2 and type I PI3K block growth and i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0656-2

    authors: Young CD,Arteaga CL,Cook RS

    更新日期:2015-12-04 00:00:00

  • Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women.

    abstract:BACKGROUND:African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-020-01297-4

    authors: Abdou Y,Attwood K,Cheng TD,Yao S,Bandera EV,Zirpoli GR,Ondracek RP,Stein L,Bshara W,Khoury T,Ambrosone CB,Omilian AR

    更新日期:2020-06-09 00:00:00

  • Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.

    abstract:INTRODUCTION:The neuron-glial antigen 2 (NG2) proteoglycan promotes pericyte recruitment and mediates pericyte interaction with endothelial cells. In the absence of NG2, blood vessel development is negatively impacted in several pathological models. Our goal in this study was to determine the effect of NG2 ablation on ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3174

    authors: Gibby K,You WK,Kadoya K,Helgadottir H,Young LJ,Ellies LG,Chang Y,Cardiff RD,Stallcup WB

    更新日期:2012-04-24 00:00:00

  • Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.

    abstract:INTRODUCTION:Activated leukocyte cell adhesion molecule (ALCAM) (CD166) is an immunoglobulin molecule that has been implicated in cell migration. The present study examined the expression of ALCAM in human breast cancer and assessed its prognostic value. METHODS:The immunohistochemical distribution and location of ALC...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr815

    authors: King JA,Ofori-Acquah SF,Stevens T,Al-Mehdi AB,Fodstad O,Jiang WG

    更新日期:2004-01-01 00:00:00

  • Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.

    abstract:BACKGROUND:Women with breast cancer who have multiple affected relatives are more likely to have inherited genetic risk factors for the disease. All the currently known genetic risk factors for breast cancer account for less than half of the average familial risk. Furthermore, the genetic factor(s) underlying an increa...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0825-6

    authors: Walker LC,Pearson JF,Wiggins GA,Giles GG,Hopper JL,Southey MC

    更新日期:2017-03-16 00:00:00

  • Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

    abstract::Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1149-5

    authors: Rossi L,Biagioni C,McCartney A,Migliaccio I,Curigliano G,Sanna G,Moretti E,Minisini AM,Cinieri S,Tondini C,Arpino G,Bernardo A,Martignetti A,Risi E,Pestrin M,Boni L,Benelli M,Biganzoli L,Di Leo A,Malorni L

    更新日期:2019-05-29 00:00:00

  • Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

    abstract::Accumulating evidence suggests that many cancers, including BRCA1- and BRCA2-associated breast cancers, are deficient in DNA repair processes. Both hereditary and sporadic breast cancers have been found to have significant downregulation of repair factors. This has provided opportunities to exploit DNA repair deficien...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2566

    authors: Rowe BP,Glazer PM

    更新日期:2010-01-01 00:00:00

  • GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.

    abstract:INTRODUCTION:Recent studies have demonstrated that members of the GATA-binding protein (GATA) family (GATA4 and GATA5) might have pivotal roles in the transcriptional upregulation of mucin genes (MUC2, MUC3 and MUC4) in gastrointestinal epithelium. The zinc-finger GATA3 transcription factor has been reported to be invo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1617

    authors: Abba MC,Nunez MI,Colussi AG,Croce MV,Segal-Eiras A,Aldaz CM

    更新日期:2006-01-01 00:00:00

  • In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.

    abstract:BACKGROUND:Although recent models suggest that the detection of Circulating Tumor Cells (CTC) in epithelial-to-mesenchymal transition (EM CTC) might be related to disease progression in metastatic breast cancer (MBC) patients, current detection methods are not efficient in identifying this subpopulation of cells. Furth...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-016-0687-3

    authors: Bulfoni M,Gerratana L,Del Ben F,Marzinotto S,Sorrentino M,Turetta M,Scoles G,Toffoletto B,Isola M,Beltrami CA,Di Loreto C,Beltrami AP,Puglisi F,Cesselli D

    更新日期:2016-03-09 00:00:00

  • Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study.

    abstract:INTRODUCTION:The ataxia telangiectasia mutated (ATM) gene is a tumor suppressor gene with functions in cell cycle arrest, apoptosis, and repair of DNA double-strand breaks. Based on family studies, women heterozygous for mutations in the ATM gene are reported to have a fourfold to fivefold increased risk of breast canc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr809

    authors: Tamimi RM,Hankinson SE,Spiegelman D,Kraft P,Colditz GA,Hunter DJ

    更新日期:2004-01-01 00:00:00

  • Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.

    abstract:INTRODUCTION:The invasive, mesenchymal phenotype of CD44posCD24neg breast cancer cells has made them a promising target for eliminating the metastatic capacity of primary tumors. It has been previously demonstrated that CD44neg/lowCD24pos breast cancer cells lack the ability to give rise to their invasive CD44posCD24ne...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2449

    authors: Meyer MJ,Fleming JM,Ali MA,Pesesky MW,Ginsburg E,Vonderhaar BK

    更新日期:2009-01-01 00:00:00

  • Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.

    abstract:INTRODUCTION:The chromodomain helicase DNA binding protein 5 (CHD5) has recently been identified as a tumor suppressor in a mouse model. The CHD5 locus at 1p36 is deleted, and its mutation has been detected in breast cancer. We, therefore, evaluated whether CHD5 plays a role in human breast cancer. METHODS:We screened...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3182

    authors: Wu X,Zhu Z,Li W,Fu X,Su D,Fu L,Zhang Z,Luo A,Sun X,Fu L,Dong JT

    更新日期:2012-05-08 00:00:00

  • Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.

    abstract:INTRODUCTION:Aberrant expression of the embryonic stem cell marker Sox2 has been reported in breast cancer (BC). We previously identified two phenotypically distinct BC cell subsets separated based on their differential response to a Sox2 transcription activity reporter, namely the reporter-unresponsive (RU) and the mo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0470-2

    authors: Jung K,Wang P,Gupta N,Gopal K,Wu F,Ye X,Alshareef A,Bigras G,McMullen TP,Abdulkarim BS,Lai R

    更新日期:2014-11-08 00:00:00

  • HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.

    abstract:INTRODUCTION:Classification of breast cancers according to the HER-2 oncogene status is of central importance in the selection of post-surgical therapies. A decrease in the proportion of HER-2-positive breast cancer has been suspected, but no data on the incidence trends at population level have been reported. METHODS...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2322

    authors: Köninki K,Tanner M,Auvinen A,Isola J

    更新日期:2009-01-01 00:00:00

  • DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.

    abstract:INTRODUCTION:Aberrant activation of Wnt/β-catenin signaling plays an important role in the pathogenesis of breast cancer. DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/β-catenin signaling through interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in brea...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3399

    authors: Yin X,Xiang T,Li L,Su X,Shu X,Luo X,Huang J,Yuan Y,Peng W,Oberst M,Kelly K,Ren G,Tao Q

    更新日期:2013-03-12 00:00:00

  • Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    abstract:INTRODUCTION:Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome. Our goal is to develop a universal biomarker that distinguishes patients at high risk across all breast cancer subtypes. We previous...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2156

    authors: Habibi G,Leung S,Law JH,Gelmon K,Masoudi H,Turbin D,Pollak M,Nielsen TO,Huntsman D,Dunn SE

    更新日期:2008-01-01 00:00:00

  • Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.

    abstract::Recent insights into the molecular and cellular mechanisms underlying cancer development have revealed that immune cells functionally regulate epithelial cancer development and progression. Moreover, accumulated clinical and experimental data indicate that the outcome of an immune response toward an evolving breast ne...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1746

    authors: DeNardo DG,Coussens LM

    更新日期:2007-01-01 00:00:00

  • The combined effect of mammographic texture and density on breast cancer risk: a cohort study.

    abstract:BACKGROUND:Texture patterns have been shown to improve breast cancer risk segregation in addition to area-based mammographic density. The additional value of texture pattern scores on top of volumetric mammographic density measures in a large screening cohort has never been studied. METHODS:Volumetric mammographic den...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0961-7

    authors: Wanders JOP,van Gils CH,Karssemeijer N,Holland K,Kallenberg M,Peeters PHM,Nielsen M,Lillholm M

    更新日期:2018-05-02 00:00:00

  • Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry.

    abstract:BACKGROUND:Approximately 100 common breast cancer susceptibility alleles have been identified in genome-wide association studies (GWAS). The utility of these variants in breast cancer risk prediction models has not been evaluated adequately in women of Asian ancestry. METHODS:We evaluated 88 breast cancer risk variant...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-016-0786-1

    authors: Wen W,Shu XO,Guo X,Cai Q,Long J,Bolla MK,Michailidou K,Dennis J,Wang Q,Gao YT,Zheng Y,Dunning AM,García-Closas M,Brennan P,Chen ST,Choi JY,Hartman M,Ito H,Lophatananon A,Matsuo K,Miao H,Muir K,Sangrajrang S,

    更新日期:2016-12-08 00:00:00

  • Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.

    abstract:BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedb...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01262-1

    authors: Tank A,Peterson HM,Pera V,Tabassum S,Leproux A,O'Sullivan T,Jones E,Cabral H,Ko N,Mehta RS,Tromberg BJ,Roblyer D

    更新日期:2020-03-13 00:00:00

  • Breast cancer prognostic classification in the molecular era: the role of histological grade.

    abstract::Breast cancer is a heterogeneous disease with varied morphological appearances, molecular features, behavior, and response to therapy. Current routine clinical management of breast cancer relies on the availability of robust clinical and pathological prognostic and predictive factors to support clinical and patient de...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2607

    authors: Rakha EA,Reis-Filho JS,Baehner F,Dabbs DJ,Decker T,Eusebi V,Fox SB,Ichihara S,Jacquemier J,Lakhani SR,Palacios J,Richardson AL,Schnitt SJ,Schmitt FC,Tan PH,Tse GM,Badve S,Ellis IO

    更新日期:2010-01-01 00:00:00

  • High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.

    abstract:INTRODUCTION:Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. In breast carcinoma, FAK overexpression has been linked to cancer progression but the prognostic relevance remains unknown. In particular, with regard to lymph node-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr977

    authors: Schmitz KJ,Grabellus F,Callies R,Otterbach F,Wohlschlaeger J,Levkau B,Kimmig R,Schmid KW,Baba HA

    更新日期:2005-01-01 00:00:00

  • Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

    abstract::Zoledronic acid (ZA) is an imidazole-containing bisphosphonate that has been extensively studied as an osteoclast inhibitor. ZA decreases bone turnover and has been effective in limiting osteolysis in metastatic cancers, including breast cancer. Recent clinical trials that demonstrated enhancement of disease-free surv...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3223

    authors: Steinman RA,Brufsky AM,Oesterreich S

    更新日期:2012-09-21 00:00:00

  • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

    abstract:BACKGROUND:We previously performed a case-control genome-wide association study in women treated with selective estrogen receptor modulators (SERMs) for breast cancer prevention and identified single nucleotide polymorphisms (SNPs) in ZNF423 as potential biomarkers for response to SERM therapy. The ZNF423rs9940645 SNP,...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0890-x

    authors: Qin S,Ingle JN,Liu M,Yu J,Wickerham DL,Kubo M,Weinshilboum RM,Wang L

    更新日期:2017-08-18 00:00:00